| [1] |
Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1): 9-29.
|
| [2] |
Varughese S, Jahangir KS, Simpson CE, et al. A paradigm shift in the treatment of advanced non-small cell lung cancer[J]. Am J Med Sci, 2012, 344(2): 147-50.
|
| [3] |
Siegfried JM, Gubish CT, Rothstein ME, et al. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer[J]. J Thorac Oncol, 2012, 7(3): 485-95.
|
| [4] |
Nolen BM, Brand RE, Prosser D, et al. Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study[J]. PLoS One, 2014, 9(4): e94928.
|
| [5] |
Lou E, Johnson M, Sima C, et al. Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer[J]. Cancer Biomark, 2014, 14(4): 207-14.
|
| [6] |
Fiala O, Pesek M, Finek J, et al. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib[J]. Anticancer Res, 2014, 34(6): 3205-10.
|
| [7] |
Lei DS, Pei F, Yu J, et al. Evaluation value of tissue polypeptide antigen combined with ProGRP, CEA, NSE, SCC and CYFRA21-1 on patients with lung cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2015, 42(5): 488-92. [雷旦生, 裴锋, 喻晶, 等. 组织多肽 抗原联合ProGRP、CEA、NSE、SCC、CYFRA21-1在肺癌诊 治中的价值[J]. 肿瘤防治研究, 2015, 42(5): 488-92.]
|
| [8] |
Moreira AL, Eng J. Personalized therapy for lung cancer[J]. Chest, 2014, 146(6): 1649-57.
|
| [9] |
Pang L, Wang J, Jiang Y, et al. Decreased levels of serum cytokeratin 19 fragment CYFRA 21-1 predict objective response to chemotherapy in patients with non-small cell lung cancer[J]. Exp Ther Med, 2013, 6(2): 355-60.
|
| [10] |
Dai H, Liu J, Liang L, et al. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers[J]. Respirology, 2014, 19(5): 707-13.
|
| [11] |
Qin HF, Qu LL, Liu H, et al. Serum CEA level change and its significance before and after Gefitinib therapy on patients with advanced non-small cell lung cancer[J]. Asian Pac J Cancer Prev, 20 13, 14(7): 4205-8.
|
| [12] |
Cedrés S, Nuñez I, Longo M, et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC)[J]. Clin Lung Cancer, 2011, 12(3): 172-9.
|
| [13] |
Zhao J, Zhao M, Jin B, et al. Tumor response and survival in patients with advanced non-small-cell lung cancer: the predictive value of chemotherapy-induced changes in fibrinogen[J]. BMC Cancer, 2012, 12: 330.
|
| [14] |
Szturmowicz M, Rudziński P, Kacprzak A, et al. Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer[J]. Pneumonol Alergol Pol, 2014, 82(5): 422-9.
|
下载:
